Research use only. This page summarizes publicly registered trial data. It is not dosing or administration guidance, and eloralintide is not approved for human use at any dose, by any route.

Short answer: Lilly’s Phase 2 trial (NCT06230523) tested once-weekly subcutaneous doses of 1mg, 3mg, 6mg, and 9mg (plus a dose-escalation arm) against placebo over 48 weeks, with efficacy-estimand weight reductions of 9.5% to 20.1% across the active arms versus 0.4% for placebo. A separate combination trial with tirzepatide reported -23.3% weight change in people with type 2 diabetes. Phase 3 dosing, once published, may differ from these Phase 2 arms.

• All active-dose arms (1mg–9mg once weekly) reportedly met the trial’s primary endpoint for weight reduction.
• The 9mg arm produced the largest reported reduction at roughly 20% over 48 weeks (on-treatment/efficacy estimand).
• Half-life after a single dose is 12.9 to 15.3 days, but no registered trial has tested less-than-weekly dosing.
• Five ENLIGHTEN-branded Phase 3 obesity trials are currently enrolling, with estimated primary completion January to June 2028.

Last verified October 2026. Sources are listed at the end. For laboratory and research use only. Nothing here is medical or legal advice.

Trial design

Eli Lilly’s Phase 2 trial (ClinicalTrials.gov identifier NCT06230523) enrolled 263 adults with obesity or overweight, without type 2 diabetes, at sites across the United States. Participants were randomized to placebo or to one of several once-weekly subcutaneous eloralintide dose arms, including a dose-escalation arm, over a 48-week treatment period. Results were presented at ObesityWeek 2025 and published in The Lancet (Billings et al., 2025).

Dose arms tested

Lilly’s press release describes active-dose arms of 1mg, 3mg, 6mg, and 9mg once weekly, plus a dose-escalation arm, compared against placebo. All active-dose arms reportedly met the trial’s primary endpoint for weight reduction.

How these numbers compare to other amylin and incretin drugs

Eloralintide’s on-treatment phase 2 result (about -20% at 48 weeks at the top dose) sits beside retatrutide’s -24.2% at 48 weeks in its own phase 2 trial, tirzepatide’s -20.9% at 72 weeks, and semaglutide’s -14.9% at 68 weeks in their respective phase 3 programs. These trials differ in length, size, population, and counting method (on-treatment vs. all-randomized), so none of these figures should be read as a head-to-head comparison — no such trial has been published for eloralintide against any of them.

Safety observed at these doses

The most commonly reported adverse events across dose arms were mild to moderate nausea and fatigue. In the Phase 2 trial, nausea reportedly ranged from 11% to 64% by arm (14% on placebo) and fatigue from 0% to 46% (12% on placebo), consistent with the gastrointestinal tolerability profile generally seen in amylin- and incretin-class compounds during dose titration. About 10% of participants stopped treatment because of an adverse event.

What comes next

Following this Phase 2 readout, Lilly moved eloralintide into Phase 3-stage development, including an obstructive sleep apnea trial (NCT07369011), a knee osteoarthritis pain study, a pharmacokinetic study in healthy participants (NCT07701083), and five ENLIGHTEN-branded Phase 3 obesity trials, with estimated primary completion between January and June 2028 on public ClinicalTrials.gov records. Phase 3 dosing protocols, once registered and published, may differ from the Phase 2 arms summarized above.

Why this page doesn’t give dosing advice

Eloralintide is not approved for human use at any dose, by any route, for any indication. The figures above describe what was tested in a specific, supervised clinical trial under medical monitoring — they are not a recommendation, protocol, or guide for personal use. Dosing charts circulating on vendor or forum pages are written by third parties, not Lilly, and typically convert trial arms into unverified “protocols.” Anyone encountering eloralintide marketed for self-administration outside of a registered clinical trial should treat that as a red flag, since no approved supply chain for this compound currently exists.

Sources

All sources read and verified October 2026.

• Billings LK, et al. Eloralintide Phase 2. The Lancet 2025. DOI: 10.1016/S0140-6736(25)02155-5. ClinicalTrials.gov NCT06230523.
• Eli Lilly. EloraTZP Phase 2b release, September 30, 2026: PR Newswire.
• ClinicalTrials.gov, eloralintide (LY3841136) records: search.